The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas
- 26 Downloads
To evaluate the expression of programmed cell death-ligand 1 (PD-L1) and CD8 in high-grade endometrial carcinomas and relate it to several clinicopathological parameters.
One hundred and one (101) patients with high-grade endometrial carcinomas who were completely surgically staged were included in this study. PD-L1 and CD8 + expression was evaluated by immunohistochemistry.
In our cohort, 47 women (46.5%) had endometrioid carcinomas and 54 patients (53.5%) were diagnosed with non-endometrioid cancers. In endometrioid carcinomas, there was a significantly higher rate of positivity for PD-L1 expression (p = 0.042) and of intraepithelial CD8 + cell counts (p = 0.004) as opposed to non-endometrioid cancers. There were no significant relationships with any of the other clinicopathological features under study. Univariate and multivariate analysis revealed that only high intraepithelial CD8 + counts (p = 0.01) was associated with longer progression-free survival. Tumors positive for PD-L1 and high intraepithelial CD8 expression were mainly of endometrioid histology, whilst PD-L1-positive/CD8 low and PD-L1-negative/CD8 low tumors were mostly non-endometrioid carcinomas (p = 0.01). PD-L1 negative/CD8 high tumors had the longest progression-free survival (p = 0.032).
In grade 3 endometrial carcinomas, both of endometrioid and non-endometrioid type, high intraepithelial CD8 + counts represent an independent favorable prognostic factor and when related to PD-L1-negative tumors, a longer progression-free survival can be predicted. Immunotherapy could probably be considered for PD-L1-positive/CD8 + high tumors, which were mostly of endometrioid histology.
KeywordsPD-L1 CD8 Endometrial cancer
This research work was supported by the Onassis Foundation—Scholarship ID: G ZO 001-1/2018-2019.
Compliance with ethical standards
Conflict of interest
Onassis Foundation did not influence on the decision to submit this manuscript or on its content. We declare that we have no conflict of interest.
- 9.Suemori T, Susumu N, Iwata T et al (2015) Intratumoral CD8+ lymphocyte infiltration as a prognostic factor and its relationship with cyclooxygenase 2 expression and microsatellite instability in endometrial cancer. Int J Gynecol Cancer 25(7):1165–1172. https://doi.org/10.1097/IGC.0000000000000482 CrossRefGoogle Scholar
- 11.Iurchenko NP, Glushchenko NM, Buchynska LG (2014) Comprehensive analysis of intratumoral lymphocytes and FOXP3 expression in tumor cells of endometrial cancer. Exp Oncol 36(4):262–266Google Scholar
- 14.Howitt BE, Shukla SA, Sholl LM et al (2015) Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 1(9):1319–1323. https://doi.org/10.1001/jamaoncol.2015.2151 CrossRefGoogle Scholar
- 28.US Food and Drug Administration (2017) FDA approves first cancer treatment for any solid tumor with a specific genetic feature. US Food and Drug Administration, Silver SpringGoogle Scholar
- 31.Eggink FA, Van Gool IC, Leary A et al (2017) Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology 6(2):e1264565. https://doi.org/10.1080/2162402X.2016.1264565 CrossRefGoogle Scholar
- 41.Tamura T, Ohira M, Tanaka H et al (2015) Programmed death-1 ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancer. Anticancer Res 35(10):5369–5376Google Scholar
- 43.Bellone S, Bignotti E, Lonardi S et al (2017) Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecol Oncol 144(1):146–152. https://doi.org/10.1016/j.ygyno.2016.11.023 CrossRefGoogle Scholar
- 45.Cermakova P, Melichar B, Tomsova M et al (2014) Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma. Anticancer Res 34(10):5555–5561Google Scholar
- 46.Hendry S, Salgado R, Gevaert T et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol 24(5):235–251. https://doi.org/10.1097/PAP.0000000000000162 CrossRefGoogle Scholar
- 49.Hendry S, Salgado R, Gevaert T et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24(6):311–335. https://doi.org/10.1097/PAP.0000000000000161 CrossRefGoogle Scholar